Adamco Products
Oral Hypoglycemic.


Each modified release tablet contains 30mg gliclazide

Adamicron MR is an extended-release formula of gliclazide.
Gliclazide is a β-cell-selective sulfonylurea which provides global metabolic and vascular treatment for patients with type 2 diabetes. It differs from other hypoglycemic oral compounds in that it has a dual pharmacological activity: it has both metabolic and original microvascular properties:

  1. Metabolic Properties: Gliclazide has an insulin-secreting action and potentiates the insulin-secreting effect of glucose. The risk of hypoglycemia is low thanks to the progressive hypoglycemic action of gliclazide and its half-life of 12 hours.
  2. Microvascular Properties: Gliclazide induces a decrease in platelet adhesiveness and aggregation, a reduction in platelet turnover, and a normalization of endothelial fibrinolytic activity.
Studies have shown that gliclazide significantly slows down the progression of diabetes retinopathy, gliclazide produces a significant decrease in proteinuria and a better control of blood glucose without modifying renal function.

The newly formulated gliclazide in Adamicron MR offers a once-daily dosage regimen. It offers efficient 24-hour blood glucose control with excellent acceptability by better matching the release of short-acting sulfonylurea to the circadian glycemic profiles of type 2 diabetic patients. The innovative formulation, given at breakfast, ensures that gliclazide blood levels are highest during the prandial daytime period, and relatively reduced during the fasting hours.

In addition, the benefits of the new formula include:

  • High absolute bioavailability of 97% which has allowed optimization of the new dose per tablet to 30mg.
  • Reproducible absorption irrespective of the total daily dose and of the food intake.
  • 24-hour glycemic control with very low incidence of hypoglycemia.
  • Avoidance of nocturnal hypoglycemic episodes.


30 to 120 mg (1 to 4 tablets) depending on response, once daily with breakfast, including in elderly patients or those with mild-to-moderate renal failure.


Possible severe hypoglycemia requiring urgent IV glucose and monitoring.

read more